BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19906926)

  • 1. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
    Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
    J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
    Guse K; Diaconu I; Rajecki M; Sloniecka M; Hakkarainen T; Ristimäki A; Kanerva A; Pesonen S; Hemminki A
    Gene Ther; 2009 Aug; 16(8):1009-20. PubMed ID: 19440223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
    Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
    PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
    Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
    Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
    McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
    Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
    Lun X; Ruan Y; Jayanthan A; Liu DJ; Singh A; Trippett T; Bell J; Forsyth P; Johnston RN; Narendran A
    Mol Oncol; 2013 Oct; 7(5):944-54. PubMed ID: 23816608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
    Hou W; Chen H; Rojas J; Sampath P; Thorne SH
    Int J Cancer; 2014 Sep; 135(5):1238-46. PubMed ID: 24474587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new oncolytic
    Ahmed J; Chard LS; Yuan M; Wang J; Howells A; Li Y; Li H; Zhang Z; Lu S; Gao D; Wang P; Chu Y; Al Yaghchi C; Schwartz J; Alusi G; Lemoine N; Wang Y
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.
    Chard LS; Maniati E; Wang P; Zhang Z; Gao D; Wang J; Cao F; Ahmed J; El Khouri M; Hughes J; Wang S; Li X; Denes B; Fodor I; Hagemann T; Lemoine NR; Wang Y
    Clin Cancer Res; 2015 Jan; 21(2):405-16. PubMed ID: 25416195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer.
    Deng L; Yang X; Fan J; Ding Y; Peng Y; Xu D; Huang B; Hu Z
    Oncol Res; 2021 Mar; 28(6):579-590. PubMed ID: 32641200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
    Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
    Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
    Chalikonda S; Kivlen MH; O'Malley ME; Eric Dong XD; McCart JA; Gorry MC; Yin XY; Brown CK; Zeh HJ; Guo ZS; Bartlett DL
    Cancer Gene Ther; 2008 Feb; 15(2):115-25. PubMed ID: 18084242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
    Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
    Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.